4DMedical (ASX:4DX) secured a contract with the US Department of Defense to conduct a pilot program using its CT Ventilation-Perfusion technology, ahead of the US Food and Drug Administration's clearance of the technology, according to a Monday filing with the Australian bourse.
The technology, which provides a detailed view of lung ventilation and perfusion without radioactive isotopes, will be used to assess lung function and detect conditions like chronic obstructive pulmonary disease and chronic thromboembolic hypertension in 80 active-duty military personnel, the filing said.
Under the agreement, 4DMedical will provide a fixed number of scan analysis reports, helping with the early detection and management of lung conditions, particularly in service members exposed to hazardous environments during military operations.
Financial terms were not disclosed.
Shares of the company soared past 9% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.